VWA9 Inhibitors
WA9 inhibitors represent a niche within the broader spectrum of biochemical research focusing on the modulation of specific protein interactions. The von Willebrand factor type A (VWA) domain is a protein module found in various organisms and is known for its role in mediating adhesion and protein-protein interactions. The VWA9 subtype, in particular, refers to a distinct variant within this family, characterized by a specific sequence and structural configuration that enables it to engage in unique molecular interactions. Inhibitors targeting VWA9 are designed to selectively bind to this domain, effectively modulating its natural function. The design of such inhibitors is a complex process, typically requiring a deep understanding of the domain's three-dimensional structure, the dynamics of its interaction sites, and the nature of its binding partners.
The development of VWA9 inhibitors hinges on advanced techniques in molecular biology, computational chemistry, and structural biology. By utilizing tools such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking simulations, researchers can elucidate the detailed arrangements of atoms within the VWA9 domain and identify key residues critical for its activity. Inhibitors are typically small molecules or peptides that can snugly fit into the active or binding site of the VWA9 domain, thereby preventing it from engaging with its natural ligands. The specificity of these inhibitors is paramount; they must closely mimic or compete with the natural substrates of the domain without affecting other VWA types or unrelated proteins. This specificity is achieved through iterative cycles of design, synthesis, and testing, where the molecular structure of the inhibitor is refined to optimize its interaction with the VWA9 domain and minimize off-target effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its chaperone activity. As Hsp90 is involved in the folding of client proteins, the inhibition of Hsp90 can lead to the degradation of client proteins, including VWA9, thus reducing its functional activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A, a steroidal lactone, is known to disrupt proteasomal activity. By impairing the proteasome, the degradation of misfolded or damaged proteins is inhibited, which can indirectly lead to the reduced function of VWA9 due to accumulation of non-functional proteins that may disrupt cellular homeostasis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway. Inhibition of this pathway can lead to reduced protein synthesis and promote protein degradation pathways, potentially decreasing the levels and activity of VWA9. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTORC1, which is a central regulator of cell growth and protein synthesis. Downregulation of this pathway could lead to a decrease in the expression and activity of proteins such as VWA9. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein biosynthesis by interfering with the translocation step in protein synthesis, potentially leading to reduced levels of VWA9. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the exchange of GDP to GTP on ARF proteins, which may lead to mislocalization and functional inhibition of VWA9 due to its reliance on proper intracellular trafficking. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially causing a decrease in VWA9 function due to the accumulation of misfolded or damaged proteins and disruption of cellular proteostasis. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Go6976 is a potent protein kinase C (PKC) inhibitor. Since PKC is involved in numerous signaling pathways, including those regulating protein expression and turnover, inhibition of PKC could indirectly affect the stability and function of VWA9. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of p70 S6 kinase, a downstream effector of the PI3K/Akt/mTOR pathway. Inhibition of p70 S6 kinase may reduce protein synthesis, potentially decreasing the expression and activity of VWA9. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG is an analog of geldanamycin and acts as an Hsp90 inhibitor, leading to the degradation of Hsp90 client proteins. This can result in the decreased function of VWA9 if it is a client protein of Hsp90. | ||||||